Literature DB >> 23813975

Muscle-specific function of the centronuclear myopathy and Charcot-Marie-Tooth neuropathy-associated dynamin 2 is required for proper lipid metabolism, mitochondria, muscle fibers, neuromuscular junctions and peripheral nerves.

Elisa Tinelli1, Jorge A Pereira, Ueli Suter.   

Abstract

The ubiquitously expressed large GTPase Dynamin 2 (DNM2) plays a critical role in the regulation of intracellular membrane trafficking through its crucial function in membrane fission, particularly in endocytosis. Autosomal-dominant mutations in DNM2 cause tissue-specific human disorders. Different sets of DNM2 mutations are linked to dominant intermediate Charcot-Marie-Tooth neuropathy type B, a motor and sensory neuropathy affecting primarily peripheral nerves, or autosomal-dominant centronuclear myopathy (CNM) presenting with primary damage in skeletal muscles. To understand the underlying disease mechanisms, it is imperative to determine to which degree the primary affected cell types require DNM2. Thus, we used cell type-specific gene ablation to examine the consequences of DNM2 loss in skeletal muscle cells, the major relevant cell type involved in CNM. We found that DNM2 function in skeletal muscle is required for proper mouse development. Skeletal muscle-specific loss of DNM2 causes a reduction in muscle mass and in the numbers of muscle fibers, altered muscle fiber size distributions, irregular neuromuscular junctions (NMJs) and isolated degenerating intramuscular peripheral nerve fibers. Intriguingly, a lack of muscle-expressed DNM2 triggers an increase of lipid droplets (LDs) and mitochondrial defects. We conclude that loss of DNM2 function in skeletal muscles initiates a chain of harmful parallel and serial events, involving dysregulation of LDs and mitochondrial defects within altered muscle fibers, defective NMJs and peripheral nerve degeneration. These findings provide the essential basis for further studies on DNM2 function and malfunction in skeletal muscles in health and disease, potentially including metabolic diseases such as diabetes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23813975     DOI: 10.1093/hmg/ddt292

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  14 in total

1.  Development of AD-Like Pathology in Skeletal Muscle.

Authors:  X Chen; N M Miller; Z Afghah; J D Geiger
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2019-04-02

2.  Differential Expression of Several miRNAs and the Host Genes AATK and DNM2 in Leukocytes of Sporadic ALS Patients.

Authors:  Katarina Vrabec; Emanuela Boštjančič; Blaž Koritnik; Lea Leonardis; Leja Dolenc Grošelj; Janez Zidar; Boris Rogelj; Damjan Glavač; Metka Ravnik-Glavač
Journal:  Front Mol Neurosci       Date:  2018-04-04       Impact factor: 5.639

Review 3.  Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis.

Authors:  Metka Ravnik-Glavač; Damjan Glavač
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

4.  Mice carrying an analogous heterozygous dynamin 2 K562E mutation that causes neuropathy in humans develop predominant characteristics of a primary myopathy.

Authors:  Jorge A Pereira; Joanne Gerber; Monica Ghidinelli; Daniel Gerber; Luigi Tortola; Andrea Ommer; Sven Bachofner; Francesco Santarella; Elisa Tinelli; Shuo Lin; Markus A Rüegg; Manfred Kopf; Klaus V Toyka; Ueli Suter
Journal:  Hum Mol Genet       Date:  2020-05-28       Impact factor: 6.150

5.  Genetic basis and identification of candidate genes for wooden breast and white striping in commercial broiler chickens.

Authors:  Juniper A Lake; Jack C M Dekkers; Behnam Abasht
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

6.  Zebrafish as a Model to Investigate Dynamin 2-Related Diseases.

Authors:  Cinzia Bragato; Germano Gaudenzi; Flavia Blasevich; Giulio Pavesi; Lorenzo Maggi; Michele Giunta; Franco Cotelli; Marina Mora
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

7.  Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.

Authors:  Delphine Trochet; Bernard Prudhon; Maud Beuvin; Cécile Peccate; Stéphanie Lorain; Laura Julien; Sofia Benkhelifa-Ziyyat; Aymen Rabai; Kamel Mamchaoui; Arnaud Ferry; Jocelyn Laporte; Pascale Guicheney; Stéphane Vassilopoulos; Marc Bitoun
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

8.  Dynamin-2 mutations linked to Centronuclear Myopathy impair actin-dependent trafficking in muscle cells.

Authors:  Arlek M González-Jamett; Ximena Baez-Matus; María José Olivares; Fernando Hinostroza; Maria José Guerra-Fernández; Jacqueline Vasquez-Navarrete; Mai Thao Bui; Pascale Guicheney; Norma Beatriz Romero; Jorge A Bevilacqua; Marc Bitoun; Pablo Caviedes; Ana M Cárdenas
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

9.  Schwann cells, but not Oligodendrocytes, Depend Strictly on Dynamin 2 Function.

Authors:  Daniel Gerber; Monica Ghidinelli; Elisa Tinelli; Christian Somandin; Joanne Gerber; Jorge A Pereira; Andrea Ommer; Gianluca Figlia; Michaela Miehe; Lukas G Nägeli; Vanessa Suter; Valentina Tadini; Páris Nm Sidiropoulos; Carsten Wessig; Klaus V Toyka; Ueli Suter
Journal:  Elife       Date:  2019-01-16       Impact factor: 8.140

10.  Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing.

Authors:  Delphine Trochet; Bernard Prudhon; Arnaud Jollet; Stéphanie Lorain; Marc Bitoun
Journal:  Mol Ther Nucleic Acids       Date:  2016-09-13       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.